Clinical Trial Detail

NCT ID NCT04021108
Title Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Weill Medical College of Cornell University
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

gastroesophageal adenocarcinoma

Therapies

Nivolumab

Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin

Age Groups: adult senior

Additional content available in CKB BOOST